Comment
doi: 10.1038/ki.2014.354.
New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy
Affiliations
- PMID: 25549122
- DOI: 10.1038/ki.2014.354
Item in Clipboard
Comment
New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy
Kidney Int.
2015 Jan.
Free article
Abstract
The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.
Comment on
-
Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.Kidney Int. 2015 Jan;87(1):217-24. doi: 10.1038/ki.2014.240. Epub 2014 Jul 16. Kidney Int. 2015. PMID: 25029428 Clinical Trial.
-
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.Kidney Int. 2015 Jan;87(1):225-32. doi: 10.1038/ki.2014.260. Epub 2014 Jul 23. Kidney Int. 2015. PMID: 25054775 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
